Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs
- PMID: 10600597
- DOI: 10.1006/viro.1999.0049
Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs
Abstract
To evaluate the potential of SHIVs as anti-HIV-1 live vaccines, we constructed two gene-deleted SHIVs, designated SHIV-drn and SHIV-dxrn. The former lacks vpr/nef and the latter lacks vpx/vpr/nef. Four macaques that had been vaccinated with SHIV-drn were challenged with SHIV-NM-3rN, which has an HIV-1 Env that is the same as that of SHIV-drn. No challenge virus was detected by DNA PCR in, or recovered from, two of the macaques. In the other two, challenge virus was detected once and twice, respectively. Plasma viral loads were much lower than those in unvaccinated controls. Another four macaques were vaccinated with SHIV-dxrn. These macaques showed resistance but less than that of SHIV-drn-vaccinated macaques. When the two SHIV-drn-vaccinated macaques were challenged with pathogenic SHIV-89.6P, which has an HIV-1 Env that is antigenically different from that of SHIV-drn, replication of the challenge virus was restricted, and the usual decrease in the number of CD4(+) cells was prevented. In this protection, it is noteworthy that protection involved not only neutralizing antibodies and killer cell activity, but also other unknown specific and nonspecific immunity elicited by the infection.
Copyright 1999 Academic Press.
Similar articles
-
Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.Virology. 2000 Aug 15;274(1):149-64. doi: 10.1006/viro.2000.0444. Virology. 2000. PMID: 10936096
-
Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.Arch Virol. 2002 Jun;147(6):1091-104. doi: 10.1007/s00705-002-0811-9. Arch Virol. 2002. PMID: 12111421
-
Protective immunity of gene-deleted SHIVs having an HIV-1 Env against challenge infection with a gene-intact SHIV.J Med Primatol. 1999 Aug-Oct;28(4-5):242-8. doi: 10.1111/j.1600-0684.1999.tb00275.x. J Med Primatol. 1999. PMID: 10593491
-
A new approach to AIDS research and prevention: the use of gene-mutated HIV-1/SIV chimeric viruses for anti-HIV-1 live-attenuated vaccines.Microbiol Immunol. 1998;42(4):245-51. doi: 10.1111/j.1348-0421.1998.tb02279.x. Microbiol Immunol. 1998. PMID: 9623910 Review.
-
Current approaches to vaccination against human immunodeficiency viruses.Allergol Immunopathol (Madr). 1991 Jan-Feb;19(1):11-3. Allergol Immunopathol (Madr). 1991. PMID: 1719790 Review. No abstract available.
Cited by
-
Increased Virus Replication and Cytotoxicity of Non-pathogenic Simian Human Immuno Deficiency Viruses-NM-3rN After Serial Passage in a Monkey-Derived Cell Line.Ann Med Health Sci Res. 2013 Jan;3(1):55-61. doi: 10.4103/2141-9248.109490. Ann Med Health Sci Res. 2013. PMID: 23634331 Free PMC article.
-
Construction and characterization of chimeric BHIV (BIV/HIV-1) viruses carrying the bovine immunodeficiency virus gag gene.World J Gastroenterol. 2005 May 7;11(17):2609-15. doi: 10.3748/wjg.v11.i17.2609. World J Gastroenterol. 2005. PMID: 15849820 Free PMC article.
-
A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.J Virol. 2003 Jul;77(13):7244-53. doi: 10.1128/jvi.77.13.7244-7253.2003. J Virol. 2003. PMID: 12805423 Free PMC article.
-
Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus.Virology. 2009 Sep 30;392(2):260-70. doi: 10.1016/j.virol.2009.06.052. Epub 2009 Aug 3. Virology. 2009. PMID: 19647847 Free PMC article.
-
Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.J Virol. 2005 Mar;79(5):2666-77. doi: 10.1128/JVI.79.5.2666-2677.2005. J Virol. 2005. PMID: 15708986 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials